Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple
administrations of the rotigotine transdermal system. The study was conducted in adolescent
subjects (13 to <18 years of age) with idiopathic Restless Legs Syndrome (RLS).